Farmaceutische zorg bij longziekten in Indonesie.
Economische evaluaties van dure longmedicatie bij long kanker en ILD/IPF.
New medicines are evaluated by registration authorities in order to assess their benefit-risk-balance. However, not every new medicine has to have an added therapeutic value compared to already available medicines. The real clinical relevance of new medicine is therefore sometimes unclear. In this research project, we want to investigate the views of healthcare professionals (HCPs) on clinical relevance of new medicines in primary care. We will discuss healthcare professionals’ views on clinical relevance of new COPD and T2DM medicines and also describe the reasons for prescribing new medicines, which is often not in line with guideline recommendations. Finally, we want to investigate how healthcare professionals assess the clinical relevance of medicines that obtained market access in the last years, and to investigate which pharmaceutical gaps (in other words: which diseases cannot be properly treated and would demand new therapies) HCPs identify in their daily practice.Â
Drug repositioning is the application of existing drugs to new indications. We want to find out if it is possible to find new potentially effective drugs against individual tumors based on their unique gene expression patterns.
Het doel van dit onderzoek is de behandeling van longkanker verder te individualiseren en vroeg in de therapie te kunnen voorspellen wie reageert op immunotherapie.